REATORG - PARTNER OF THE ROUND TABLE "AFI: TO BE PRODUCED OR IMPORTED" AT PHARMTECH & INGREDIENTS 2021!

On November 23, within the framework of the business program of the Pharmtech & Ingredients 2021 exhibition, a round table "API: to be produced or imported" will be held.

The event will take place from 14.00 to 16.30 in Presentation Zone A, Hall 7, Pavilion 2 (Crocus Expo).

The round table will be moderated by Georgy Khachiyan, CEO of the REATORG Company. Among the speakers: Vitaly Smerdov (Vice President for Development of Mirpharm Group), Vladimir Savchuk (Director of FSUE “STC “Chemvest”), Zakhar Golant (CEO of Baltpharma LLC), Igor Narkevich (Rector of the St. Petersburg Chemical and Pharmaceutical University), Maria Ivanova (First Vice-President of the Russian Union of Chemists), Irina Vendilo (CEO of the Roskhimreaktiv Association), Ratmir Dashkin (CEO of the Mendeleev Engineering Center).

By the end of the last century, Russia had built a system for the production of all the necessary substances for the pharmaceutical industry, from low-tonnage chemicals to finished APIs. Dozens of chemical plants and machine-building enterprises worked to solve the problem of providing the industry with raw materials of their own production; specialized universities and technical schools trained qualified personnel. All this worked within the framework of the state program. With the transition to a market economy, enterprises abandoned the production of economically unprofitable products - most of the substances, and subsequently it became more profitable to purchase finished APIs abroad. As a result, Russian chemical plants and machine-building enterprises were closed, and the need for personnel decreased.

To date, only 15% of the internal needs of the pharmaceutical market for Russian-made substances are met. The current situation in the Russian pharmaceutical market is due to the high costs of API production and the low competitiveness of Russian manufacturers in comparison with other countries that supply pharmaceutical raw materials.

“The COVID-19 pandemic has actualized the need to create a full-fledged production of APIs in Russia, but this task cannot be solved without systemic government support. The program for restoring the domestic production of pharmaceutical substances may be several times more expensive than the Pharma-2020 program, but it is worth it. After all, the result of its implementation will be the national security and drug independence of the country”, - says Georgy Khachiyan, CEO of the REATORG Company.

Is it easy to restore the domestic production of pharmaceutical substances? Is it necessary to restore the system exactly as it was? How long will it take? Will pharmaceutical companies continue to buy raw materials abroad?

Experts of the round table will try to figure it out.

Dear colleagues, we invite you to take part in the event. Participation in the round table is free of charge (by e-ticket of the exhibition).